Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Syndrome and CES2[original query] |
---|
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Current drug metabolism 2008 May 9 (4): 336-43. Ribelles N, López-Siles J, Sánchez A, González E, Sánchez M J, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Apr 17 (7): 2006-13. Caronia Daniela, Martin Miguel, Sastre Javier, de la Torre Julio, García-Sáenz José Angel, Alonso Maria R, Moreno Leticia T, Pita Guillermo, Díaz-Rubio Eduardo, Benítez Javier, González-Neira An |
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaar Henk-Jan, Boven Ep |
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 1 159 114232. de With Mirjam, van Doorn Leni, Maasland Demi C, Mulder Tessa A M, Oomen-de Hoop Esther, Mostert Bianca, Homs Marjolein Y V, El Bouazzaoui Samira, Mathijssen Ron H J, van Schaik Ron H N, Bins Sand |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: